F.D.A. Approves the Drug Daraxonrasib That’s Poised to Transform Pancreatic Cancer
New York Times · LC · trust 47/100
In a key clinical trial, patients who got the pill, daraxonrasib, lived twice as long as those who got chemotherapy.
Read the original at New York Times →
Open in TruthVane →